EGFR and non-small cell lung carcinoma: The prospective phase II trial conducted by Li et al. [178] has been the first examining the efficacy and safety of adding EGFR-TKI as adjuvant therapy to pemetrexed-cisplatin in IIIA(N2) NSCLC patients.